Osteoporosis in patients with prostate cancer on long-term androgen deprivation therapy: An increasing, but under-recognized problem

BJU International

Volumn 105, Issue 8, 2010, Pages 1042-1043

  Brown, Janet E ^c   Sherriff, Jennifer M ^a   James, Nicholas D ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CORTICOSTEROID; DENOSUMAB; GONADORELIN AGONIST; PLACEBO; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TOREMIFENE; VITAMIN D; ZOLEDRONIC ACID;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; BONE DENSITY; CANCER SURVIVAL; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DIET THERAPY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRACTURE; HIGH RISK PATIENT; HUMAN; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LONG TERM CARE; NOTE; OSTEOLYSIS; OSTEOPENIA; PATIENT CARE PLANNING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RISK REDUCTION; SIDE EFFECT; TREATMENT OUTCOME; UNITED KINGDOM;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; OSTEOPOROSIS; PROSTATIC NEOPLASMS;

EID: 77950239175     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09251.x     Document Type: Note

References (12)

1. Ebeling PR. Clinical practice. Osteoporosis in men. N Engl J Med 2008 358 : 1474 1482
2. Smith MR. Osteoporosis in men with prostate cancer: now for the fracture data. J Clin Oncol 2008 26 : 4371 4372
3. Bolla M, Gonzalez D, Warde P et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl J Med 1997 337 : 295 300
4. Widmark A, Klepp O, Solberg A et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009 373 : 301 308
5. Sharifi N, Dahut WL, Steinberg SM et al. A retrospective study of the time to clinical endpoints for advanced prostate cancer. BJU Int 2005 96 : 985 989
6. Diamond TH, Higano CS, Smith MR, Guise TA, Singer FR. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer 2004 100 : 892 899
7. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005 352 : 154 164
8. Oefelein MG, Ricchiuti V, Conrad W, Resnick MI. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002 168 : 1005 1007
9. Michaelson MD, Kaufman DS, Lee H et al. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol 2007 25 : 1038 1042
10. Smith MR, Malkowicz SB, Chu F et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008 179 : 152 155
11. Smith MR, Egerdie B, Hernandez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009 361 : 745 755
12. Kanis JA, Oden A, Johansson H, Borgstrom F, Strom O, McCloskey E. FRAX and its applications to clinical practice. Bone 2009 44 : 734 743